<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9735">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05691400</url>
  </required_header>
  <id_info>
    <org_study_id>UMCC 2022.106</org_study_id>
    <secondary_id>HUM00220623</secondary_id>
    <nct_id>NCT05691400</nct_id>
  </id_info>
  <brief_title>Phase IV Multi-arm Study of CDK4/6 Pharmacokinetics in Healthy Volunteers With Known CYP3A4*22 Genotype</brief_title>
  <official_title>Phase IV Multi-arm Study of CDK4/6 Pharmacokinetics in Healthy Volunteers With Known CYP3A4*22 Genotype</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan Rogel Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Michigan Rogel Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to estimate the effect of CYP3A4*22 on the clearance and area&#xD;
      under the plasma concentration-time curve of Palbociclib, Ribociclib, and Abemaciclib&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2023</start_date>
  <completion_date type="Anticipated">August 2026</completion_date>
  <primary_completion_date type="Anticipated">August 2026</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>arms are designated based off of genotype; however, treatment is the same for each arm</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of CYP3A4*22 on the Clearance of Palbociclib</measure>
    <time_frame>2 days after initiation of Palbocicblib treatment</time_frame>
    <description>To determine the effect of CYP3A4*22 on the Clearance of Palbociclib when administered as a single dose to healthy volunteers.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of CYP3A4*22 on the Clearance of Ribociclib</measure>
    <time_frame>up to 32 days after initiation of Study drug</time_frame>
    <description>To determine the effect of CYP3A4*22 on the Clearance of Ribociclib when administered as a single dose to healthy volunteers.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of CYP3A4*22 on the CL of Abemaciclib</measure>
    <time_frame>up to 62 days after initiation of Study drug</time_frame>
    <description>To determine the effect of CYP3A4*22 on the Clearance of Abemaciclib when administered as a single dose to healthy volunteers.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>CYP3A4*22</condition>
  <arm_group>
    <arm_group_label>CYP3A4*1/*1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm will include subjects with CYP3A4*1/*1 genotype. They will receive a single oral dose of each CDK4/6 inhibitor on separate days, with at least 6 days and no more than 30 days between each medication. All participants will receive the medications in the same order: Palbociclib, Ribociclib, Abemaciclib&#xD;
Ribociclib- 200 mg tablet Abemaciclib- 150 mg tablet Palbociclib-125 mg tablet&#xD;
PK sampling will be done at the time of drug administration and at different time points until 48 hours post administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CYP3A4*1/*22</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm will include subjects with CYP3A4*1/*22 genotype. They will receive a single oral dose of each CDK4/6 inhibitor on separate days, with at least 6 days and no more than 30 days between each medication. All participants will receive the medications in the same order: Palbociclib, Ribociclib, Abemaciclib&#xD;
Ribociclib- 200 mg tablet Abemaciclib- 150 mg tablet Palbociclib-125 mg tablet&#xD;
PK sampling will be done at the time of drug administration and at different time points until 48 hours post administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CYP3A4*22/*22</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm will include subjects with CYP3A4*22/*22 genotype. They will receive a single oral dose of each CDK4/6 inhibitor on separate days, with at least 6 days and no more than 30 days between each medication. All participants will receive the medications in the same order: Palbociclib, Ribociclib, Abemaciclib&#xD;
Ribociclib- 200 mg tablet Abemaciclib- 150 mg tablet Palbociclib-125 mg tablet&#xD;
PK sampling will be done at the time of drug administration and at different time points until 48 hours post administration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palbociclib 125Mg Tab</intervention_name>
    <description>125 mg single dose</description>
    <arm_group_label>CYP3A4*1/*1</arm_group_label>
    <arm_group_label>CYP3A4*1/*22</arm_group_label>
    <arm_group_label>CYP3A4*22/*22</arm_group_label>
    <other_name>ibrance</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribociclib 200Mg Oral Tablet</intervention_name>
    <description>200 mg single dose</description>
    <arm_group_label>CYP3A4*1/*1</arm_group_label>
    <arm_group_label>CYP3A4*1/*22</arm_group_label>
    <arm_group_label>CYP3A4*22/*22</arm_group_label>
    <other_name>kisqali</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abemaciclib 150 MG Oral Tablet</intervention_name>
    <description>150 mg single dose</description>
    <arm_group_label>CYP3A4*1/*1</arm_group_label>
    <arm_group_label>CYP3A4*1/*22</arm_group_label>
    <arm_group_label>CYP3A4*22/*22</arm_group_label>
    <other_name>verzenio</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. MGI participant with genotype of interest (e.g., CYP3A4*1/*1, CYP3A4*1/*22, or&#xD;
             CYP3A4*22/*22) and consented to recontact for future research&#xD;
&#xD;
          2. Age≥18&#xD;
&#xD;
          3. Ability to understand and the willingness to sign a written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Concurrent use of a moderate or strong inhibitor or inducer of CYP3A4, based on the&#xD;
             current version of the Drug Interactions Flockhart Table™, available at this link or&#xD;
             by google search: https://drug-interactions.medicine.iu.edu/MainTable.aspx&#xD;
&#xD;
          2. Carriers another variant known to affect CYP3A4 activity, particularly CYP3A4*20.&#xD;
&#xD;
          3. Active malignancy or other disease state that would affect the pharmacokinetics of&#xD;
             CDK4/6 inhibitors or place the participant at particular risk of toxicity from a&#xD;
             single dose of a CDK4/6 inhibitor, in the opinion of the study team&#xD;
&#xD;
          4. History of allergic reaction to CDK4/6 inhibitor&#xD;
&#xD;
          5. Pregnancy or nursing female&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel L Hertz</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan Rogel Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>cancer Answer line</last_name>
    <phone>18008651125</phone>
    <email>canceranswerline@med.umich.edu</email>
  </overall_contact>
  <verification_date>April 2023</verification_date>
  <study_first_submitted>January 10, 2023</study_first_submitted>
  <study_first_submitted_qc>January 10, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 20, 2023</study_first_posted>
  <last_update_submitted>April 5, 2023</last_update_submitted>
  <last_update_submitted_qc>April 5, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Palbociclib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>will be sharing individual participant data with collaborators at Rochester for analysis only</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

